Precision Therapy of Pancreatic Cancer: From Bench to Bedside

Ciecielski, Katrin J.; Berninger, Alexandra; Algül, Hana

doi:10.1159/000509232

Cited by 2 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the combined inhibition of SHP2, upstream of KRAS, and of ERK, downstream of KRAS, was recently demonstrated to be tolerable and efficient in preclinical models of pancreatic cancer, based on which a clinical trial was initiated. 83 In summary, pancreatic cancer therapy has evolved from conventional to targeted to individualized precision treatment 74 , 84 , 85 ; hence, genetic tests in patients with pancreatic cancer should be encouraged. 86 , 87 …”

Section: The Evolution Of Pancreas Cancer Treatmentmentioning

confidence: 99%

Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care

Garami

Hegyi

2023

Function

View full text Add to dashboard Cite

Acute pancreatitis (AP) continues to present a substantial burden to patients and healthcare personnel. Despite its occasionally severe progression and high mortality rate, there is no specific therapy that could be routinely applied in patients with AP. Here, we review treatment possibilities in AP, describe how the treatment approaches have changed in pancreatic cancer as an analogy, and point out potential causes for the failure of clinical trials on AP. We highlight that instead of attempting to discover generalized treatment options that could be used in any AP patient, it is time for a paradigm shift in the treatment of AP, which would help to focus more on individual patients or specific patient subpopulations when designing clinical trials and therapeutic approaches (similarly as in pancreatic cancer). Since the recruitment of specific patient subpopulations with AP could take excessive time if clinical centers work separately, the development of precision medicine in AP would require to establish an expert committee, e.g., Pancreatitis Precision Medicine Interest Group, which could organize and coordinate the activities of the joined centers. With the joined forces of expert clinicians and leading centers, a new era could start in the treatment of AP, in which personalized treatment options could be discovered and introduced to efficiently reduce the burden of the disease on patients and healthcare workers.

show abstract